Table 1 Characteristics of 9 studies eligible for inclusion in meta-analysis
Studies | ARG/PG (or control group) | Inclusion criteria of IUGR fetuses (Fetal weight) | Disease of pregnancy | Maternal age (wk, ARG/ PG) | Gestational age at entry (wk, ARG/ PG) | Daily dose and supplement type | Course of treatment |
|---|---|---|---|---|---|---|---|
Sieroszewski et al. 2004 [14] | 78/30 | Below 10th percentile for GA | NA | 27.1 ± 5.2/29.5 ± 7.4 | 29.5 ± 2.7/31.7 ± 3.6 | 3 g/d, oral | 20 days |
Xiao and Li 2005 [8] | 30/36 | Below 10th percentile for GA | NA | 27.0 ± 3.6/27.4 ± 3.1 | 33.03 ± 2.59/33.06 ± 2.43 | 20 g/day, intravenous | 7 days |
Rytlewski et al. 2006 [15] | 30/31 | Below 10th percentile for GA | preeclampsia | 29.3 ± 6.7/29.2 ± 5.9 | 29.3 ± 3.42/29.1 ± 3.41 | 3 g/d, oral | Until delivery |
Dear et al. 2007 [9] | 42/27 | Below 10th percentile for GA | Gestational hypertension | 28 ± 5/28 ± 4 | 31.09 ± 2.98/29.88 ± 3.22 | 3 g/d, oral | Until delivery |
Ropacka et al. 2007 [12] | 24/17 | Below 10th percentile for GA | NA | 28.7 ± 5.9/28.7 ± 3.8 | 31.2 ± 3.1/29.7 ± 3.4 | 3 g/d, oral | Until delivery |
Zhang et al. 2007 [11] | 35/33 | Below 10th percentile for GA | Gestational hypertension | NA | NA | 20Â g/d, intravenous | 14Â days |
Winer et al. 2009 [10] | 21/22 | Below 3rd percentile for GA | Preeclampsia,or other disease | 28.2 ± 5.9/29.3 ± 4.2 | 28.0 ± 2.0/27.7 ± 2.1 | 14 g/d, oral | Until delivery |
Shen and Hua 2011 [13] | 30/30 | Below 10th percentile for GA | NA | NA | NA | 15Â g/d, intravenous | NA |
Singh et al. 2014 [16] | 30/30 | Below 10th percentile for GA | NA | 25.47 ± 4.3/25.17 ± 4.3 | 33.13 ± 2.9/33.0 ± 2.3 | 3 g/d, oral | 21 days |